{"Clinical Trial ID": "NCT00754325", "Intervention": ["INTERVENTION 1:", "- Fulvestrant and Dasatinib", "1st arm: Participants in this group received a drug regimen consisting of both fulvestrant and dasatinib.", "In the following cycles, 500 mg IM was administered on day 1 to 2 years.", "Dasatinib: Oral tablets, 100 mg once daily (QD), up to 2 years", "INTERVENTION 2:", "To succeed", "2nd arm: Participants in this group were given a drug regimen that consisted solely of bulvestrants.", "In the following cycles, 500 mg IM was administered on day 1 to 2 years."], "Eligibility": ["For more information on participation in Bristol-Myers Squibb (BMS) clinical trials, please visit www.BMSStudyConnect.com.", "Incorporation criteria:", "[(Estrogen receptor (ER+) and/or progesterone receptor(PgR+)]] breast cancer according to immunohistochemistry (IHC)", "A measurable or evaluable disease only", "2+ human epidermal growth factor receptor (HER2+) or HER2- breast cancer", "Men and women 18 years of age", "Women are postmenopausal or surgically sterile", "A recurrent or progressive advanced breast cancer (locally advanced or metastatic), which has progressed: (a) during or within 12 months of the completion of the treatment of the adjuvant aromatase inhibitor (IA) OR (b) during the treatment of advanced AI (metastatic treatment)", "- Exclusion criteria:", "Maternal or maternal breast-feeding", ">1 chemotherapy regimen for advanced disease", "Pleural or pericardial effusion", "Serious heart disease"], "Results": ["Performance measures:", "Number of participants with disease progression (PD) or death", "This criterion was used to assess the progression-free survival (PFS) of participants in the total evaluable population. Progress-free survival (PFS) was defined as the period from randomization to the date on which the subject was first registered as having a PNR (even if the subject stopped treating due to toxicity), or the date of death if the subject died due to any cause prior to progression.", "Timeline: Randomization date to date of initial progression of disease, or date of death (as the first case), until January 2014 (about 5 years)", "Results 1:", "Title of the arm/group: Fulvestant and Dasatinib", "Arm and group description: arms 1: Participants in this group received a drug regimen consisting of both fulvestrant and dasatinib.", "In the following cycles, 500 mg IM was administered on day 1 to 2 years.", "Dasatinib: Oral tablets, 100 mg once daily (QD), up to 2 years", "Total number of participants analysed: 50", "Type of measurement: Number", "Unit of measurement: participants 35", "Results 2:", "Title of the arm/group: Fulvestrant", "Arm/group description: arms 2: Participants in this group received a drug regimen that consisted solely of flulverizing.", "In the following cycles, 500 mg IM was administered on day 1 to 2 years.", "Total number of participants analysed: 49", "Type of measurement: Number", "Unit of measure: participants 40"], "Adverse Events": ["Undesirable Events 1:", "Total: 14/50 (28.0%)", "Angine Pectoris 0/50 (0.00 %)", "Hypertension 1/50 (2.0%)", "Increased coagulation time 0/50 (0.00 %)", "The obstacle to Bowel 1/50 (2.0%)", "Dehydration 0/50 (0.00 %)", "Diarrhoea 1/50 (2.0%)", "Nausea 3/50 (6.0%)", "- Nausea and vomiting 0/50 (0.00 %)", "Obstruction Bowel 2/50 (4.0%)", "Vomiting 3/50 (6.0%)", "Overall weakness 0/50 (0.00 %)", "Cholecystitis 1/50 (2.0%)", "Adverse Events 2:", "Total: 11/49 (22.45 per cent)", "Angina Pectoris 1/49 (2.04%)", "Hypertension 0/49 (0.00 %)", "Increased coagulation time by 1/49 (2.04%)", "Intestinal obstruction 0/49 (0.00 %)", "Dehydration 1/49 (2.04%)", "Diarrhoea 0/49 (0.00 %)", "- Nausea 0/49 (0.00 %)", "- Nausea and vomiting 1/49 (2.04%)", "Obstruction Bowel 0/49 (0.00 %)", "Vomiting 0/49 (0.00 %)", "Overall weakness 1/49 (2.04%)", "Cholecystitis 0/49 (0.00 %)"]}